Global Blood Therapeutics
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
27.3%
3 terminated/withdrawn out of 11 trials
72.7%
-13.8% vs industry average
9%
1 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Role: collaborator
Voxelotor Sickle Cell Exercise Study
Role: collaborator
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Role: lead
Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest
Role: lead
Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions
Role: lead
An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
Role: lead
Single-Dose PK Study of GBT440 in Subjects With Renal Impairment
Role: lead
A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease
Role: lead
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
Role: lead
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
Role: lead
A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects
Role: lead
All 11 trials loaded